Company intelligence / Profile preview

Eyedeal

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Eyedeal has developed and commercialized next-generation intraocular lenses using its globally patented cross-linked polyisobutylene (xPIB) material, which offers superior biocompatibility, optical clarity, mechanical properties, and reduced glistening compared to conventional IOL materials. Clinical results presented at international conferences indicate low glistening density and high stability. The company is also developing advanced orthokeratology lenses for myopia control[1][6][9].

Therapeutic areas: Ophthalmology
Modalities: DeviceImplantable medical device (specifically intraocular lens)
Industry: Implantable Medical Devices

Drug pipeline

2 assets

Eyenable

Commercial

Indications: Cataract

1 more asset in the full pipeline.

Request access →

Partnerships

University of Heidelberg

Beyond the preview

Go deeper on Eyedeal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eyedeal.

Explore the full profile